BioSpace News Archive

C4 Therapeutics, Inc., a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, announced that the Company will participate in the following upcoming investor conferences:

Synairgen plc, the respiratory company developing inhaled interferon beta for the treatment of severe viral lung infections, announces its preliminary statement of audited results for the year ended 31 December 2020.

Tonix Pharmaceuticals Holding Corp. a clinical-stage biopharmaceutical company, announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present a company overview during the Q2 Investor Summit Virtual Conference on Monday, May 17, 2021 at 3:30 p.m. ET.

Oncology programs advance with preliminary Phase 1 immunogenicity data showing robust antigen-specific CD8+ T cell response after one dose of HB-201 or HB-202; clinical results consistent with those observed in pre-clinical studies

Chemomab Therapeutics Ltd . (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced that the company’s CEO, Dr. Adi Mor will present a corporate update at Oppenheimer’s virtual Rare and Orphan Disease Summit

Leading companies continue to prioritize the modernization of quality management. With this shift well underway, six of the top 20 global pharmaceutical companies have partnered with Veeva Systems to standardize on Veeva Vault QMS for greater efficiency and better visibility across the enterprise.

IND cleared for Phase 2 study of CGT9486, a selective mutant KIT inhibitor, in Advanced Systemic Mastocytosis patients John Robinson, PhD appointed as Chief Scientific Officer to lead newly created Cogent Research team Evan Kearns, JD joined Cogent as Chief Legal Officer Ended Q1 2021 with $230.7 million in cash, sufficient to fund operations into 2024

Labcorp announced that it plans to offer, subject to market and other conditions, senior notes that are expected to be issued in two tranches.

Lexaria Bioscience Corp. , a global innovator in drug delivery platforms, announces further expansion of its intellectual property portfolio with its first-ever patent granted in India.

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion ® in the cosmetic surgery market and J-Plasma ® in the hospital surgical market, today reported financial results for its first quarter ended March 31, 2021